-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 7, Shuanglu Pharmaceutical issued an announcement stating that the company had recently received the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration for DT678 tablets
DT678 tablet is a P2Y12 receptor antagonist, which inhibits platelet aggregation and prevents thrombosis by inhibiting the binding of ADP and platelet P2Y12 receptor
At present, clopidogrel is the main drug for the prevention and treatment of cardiovascular and other arterial circulatory disorders caused by high platelet aggregation, accounting for about 81% of the total market share.